Anti-IL-1R3 antibodies for use in inflammatory conditions

Patent metadata

Field	Value
Publication number	US-11639392-B2
Application number	US-201816612052-A
Country	US
Kind code	B2
Filing date	May 8, 2018
Priority date	May 8, 2017
Publication date	May 2, 2023
Grant date	May 2, 2023

Abstract

The present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-1α, IL-Iβ, IL-33, IL-36, IL1RA and/or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediated inflammatory condition and/or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

First claim

The invention claimed is:

1. A method for treating an IL1R3-mediated inflammatory condition and/or disorder in a subject, comprising administering to the subject an antibody, or antigen binding fragment thereof, that specifically binds IL-1R3,
wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable region (VH) comprising the complementarity determining regions comprising CDR-H1, CDR-H2, and CDR-H3,
wherein the CDR-H1 region comprises an amino acid sequence set forth in SEQ ID NO: 79,
wherein the CDR-H2 region comprises an amino acid sequence set forth in SEQ ID NO: 96,
and wherein the CDR-H3 region comprises an amino acid sequence set forth in SEQ ID NO: 113; and

b) a light chain variable region (VL) comprising the complementarity determining regions comprising CDR-L1, CDR-L2, and CDR-L3,
wherein the CDR-L1 region comprises an amino acid sequence set forth in SEQ ID NO: 130,
wherein the CDR-L2 region comprises an amino acid sequence set forth in SEQ ID NO: 147, and
wherein the CDR-L3 region comprises an amino acid sequence set forth in SEQ ID NO: 175,

thereby treating the IL1R3-mediated inflammatory condition and/or disorder in the subject.

2. The method of claim 1 , wherein the VH region comprises an amino acid sequence set forth in SEQ ID NO: 28, and the VL region comprises an amino acid sequence set forth in SEQ ID NO: 174.

3. The method of claim 1 , wherein the antibody comprises a human IgG1 Fc region comprising at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

4. The method of claim 1 , wherein the antibody comprises a human IgG4 Fc region comprising at least amino acid substitutions at S228P and L235E of the human IgG4 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

5. The method of claim 1 , wherein the IL1R3-mediated inflammatory condition and/or disorder is Hidradenitis Suppurativa.

6. A method for treating an IL1R3-mediated inflammatory condition and/or disorder in a subject, comprising administering to the subject an antibody, or antigen binding fragment thereof, that specifically binds IL-1R3,
wherein the antibody or antigen binding fragment comprises:
a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 28;
b) a VL region comprising an amino acid sequence set forth in SEQ ID NO: 174; and
c) a human IgG1 Fc region comprising at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region,

wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system,
thereby treating the IL1R3-mediated inflammatory condition and/or disorder in the subject.

7. The method of claim 6 , wherein the IL1R3-mediated inflammatory condition and/or disorder is Hidradenitis Suppurativa.

8. A method for treating an IL1R3-mediated inflammatory condition and/or disorder in a subject, comprising administering to the subject an antibody, or antigen binding fragment thereof, that specifically binds IL-1R3,
wherein the antibody or antigen binding fragment comprises:
a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 28;
b) a VL region comprising an amino acid sequence set forth in SEQ ID NO: 174; and
c) a human IgG4 Fc region comprising at least amino acid substitutions at S228P and L235E of the human IgG4 Fc region,

wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system,
thereby treating the IL1R3-mediated inflammatory condition and/or disorder in the subject.

9. The method of claim 8 , wherein the IL1R3-mediated inflammatory condition and/or disorder is Hidradenitis Suppurativa.

Assignees

• Sanofi Biotechnology

Inventors

• Fischer Stephan
• Beckmann Karsten

Classifications

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title